Arcutis Canada recently announced that Health Canada has granted approval for ZORYVE, a treatment for seborrheic dermatitis, applicable to patients aged 9 and older. This approval is supported by the findings from both Phase 2 and significant Phase 3 clinical trials. The company also highlighted that the foam formulation has received approval in the United States, backed by equivalent safety and efficacy data.
"We are honored to be the first company in over twenty years to introduce a non-steroidal treatment specifically designed to tackle critical challenges in disease management, thereby enhancing patient outcomes," stated Frank Watanabe, President and CEO of Arcutis.
